Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
Sarah M. Carpanini(UK Dementia Research Institute), B. Paul Morgan(UK Dementia Research Institute)
Cited by 97
Related Papers
The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans
|Brain Behavior and Immunity|2025|11
Faculty Opinions recommendation of Cardioprotection by nicotinamide mononucleotide (NMN): Involvement of glycolysis and acidic pH.
|Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature|2019|0
Faculty Opinions recommendation of Nitrosative stress drives heart failure with preserved ejection fraction.
|Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature|2019|0